Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 10/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129416 | 0.89 | NOS2 (0.46) | MAPTNOS2P2RY12 | |
| SCHEMBL5193373 | 0.88 | NOS2 (0.44) | MAPTNOS2LMNA | |
| SCHEMBL6301303 | 0.85 | ACACB (0.41) | NOS2ACACB | |
| SCHEMBL5194986 | 0.82 | NOS2 (0.44) | NOS2 | |
| SCHEMBL5193378 | 0.78 | NOS2 (0.48) | NOS2 | |
| SCHEMBL5192683 | 0.77 | NOS2 (0.55) | NOS2 | |
| SCHEMBL5190133 | 0.77 | NOS2 (0.58) | NOS2 | |
| SCHEMBL5195253 | 0.77 | NOS2 (0.53) | NOS2 | |
| SCHEMBL5192601 | 0.77 | NOS2 (0.47) | NOS2 | |
| SCHEMBL5192801 | 0.76 | NOS2 (0.57) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | MAPT 3264/4885NOS2 2/4885P2RY12 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.